{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015621","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.208445+00:00","generated_at":"2026-06-10T21:47:52.275921+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Aprea Therapeutics updates corporate presentation for Sep 2023; details not disclosed in excerpt","bullets":["Filing consists solely of an updated corporate slide deck dated September 2023.","Presentation title indicates focus on precision oncology and synthetic lethality.","No financial results, guidance, leadership changes, or deal announcements in the filing.","Exhibit excerpt does not contain specific trial data or operational milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015621","json":"https://secwatch.observer/filing/0001558370-23-015621.json","markdown":"https://secwatch.observer/filing/0001558370-23-015621.md","text":"https://secwatch.observer/filing/0001558370-23-015621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023015621/0001558370-23-015621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023015621/apre-20230911x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:47:52.275921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}